Barclays Maintains Overweight on Omada Health, Lowers Price Target to $17
Omada Health, Inc. +2.81%
Omada Health, Inc. OMDA | 12.46 | +2.81% |
Barclays analyst Saket Kalia maintains Omada Health (NASDAQ:
OMDA) with a Overweight and lowers the price target from $22 to $17.
